8-K: Unity Biotechnology Issues Special Preferred Stock to Facilitate Dissolution Vote

Unity Biotechnology, Inc. has issued a Series A Preferred Share to its sole director, granting significant voting power to align with common stockholder votes on a proposed company dissolution.

Summary

• Unity Biotechnology, Inc. entered into a Purchase Agreement on July 22, 2025, to sell one share of newly designated Series A Preferred Stock to Craig R. Jalbert, the company's President, Secretary, and sole director, for $1.00.
• The Series A Preferred Share, effective July 21, 2025, carries 600,000,000 votes, but its votes on any Dissolution Proposal must be cast in the same proportion as votes of common stock.
• The Board of Directors determined on June 27, 2025, that dissolving the company is in its and its stockholders' best interests and approved seeking stockholder approval for a Plan of Dissolution at a special meeting.
• The company's common stock was suspended from trading on Nasdaq on July 9, 2025, and now trades on the OTC Pink Marketplace under the symbol UNBX; a Form 25 will be filed to delist the common stock from Section 12(b) registration.
• The Series A Preferred Share is not convertible, is not entitled to liquidation distributions, and has limited transferability, automatically transferring back to the company for no consideration upon stockholder approval of the Dissolution Proposal.
• Following the issuance of the Series A Preferred Share, stockholder approval for dissolution now requires affirmative approval from a majority of the voting power of common stock and Series A Preferred, voting together as a single class.

Sentiment

Score: 1

Explanation: The company is undergoing dissolution and delisting, which are highly negative events for shareholders, indicating a complete failure of the business model or operations.

Negatives

• The company's common stock was suspended from trading on The Nasdaq Stock Market LLC and now trades on the OTC Pink Marketplace, indicating a significant downgrade in market access and liquidity.
• The Board of Directors has determined that it is in the best interests of the company and its stockholders that the company be dissolved, signaling the end of the company's operations.
• The company intends to file a Certificate of Dissolution, initiating the formal process of winding down and liquidating assets.

Risks

• The company's ability to obtain stockholder approval of the Dissolution Proposal is not guaranteed.
• There is a risk that the company may not realize any value from the sale, license, monetization, and/or divestiture of its assets and technologies.
• Other risks are described in the company's filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Future Outlook

The company plans to hold a special meeting of stockholders as soon as reasonably practicable to seek approval for its dissolution. If approved, a Certificate of Dissolution will be filed, initiating the wind-down process. The company also aims to sell, license, monetize, or divest its assets and technologies to potentially realize benefits for creditors and stockholders.

Management Comments

• The Board of Directors determined that it is in the best interests of the company and its stockholders that the company be dissolved in accordance with the DGCL pursuant to a Plan of Dissolution.

Industry Context

This announcement reflects a company undergoing a complete wind-down, a stark contrast to the typical growth and development focus within the biotechnology sector. It indicates a failure to achieve sustainable operations or successful product development, leading to a decision to liquidate rather than continue operations or seek a merger.

Corporate Governance

Related Party Transactions

• The company entered into a Purchase Agreement to sell one share of Series A Preferred Stock to Craig R. Jalbert, who is the company's President, Secretary, and sole director, for $1.00.

Stakeholder Impact

• Shareholders: Face significant negative impact due to delisting and the impending dissolution, which typically results in liquidation value that may be less than current market value or even zero for common stockholders.
• Creditors: The company's stated intent to realize potential benefit for its creditors through asset monetization suggests an effort to satisfy obligations before or during dissolution.
• Employees: While not explicitly mentioned, a dissolution process typically leads to job losses as operations cease.

Next Steps

• File a Form 25 with the SEC to delist the company's common stock from registration under Section 12(b) of the Exchange Act.
• Hold a special meeting of stockholders as soon as reasonably practicable to seek approval for the Dissolution Proposal.
• If the Dissolution Proposal is approved, file a Certificate of Dissolution with the Secretary of State of the State of Delaware.
• Potentially sell, license, monetize, and/or divest one or more of the company's assets and technologies.
• File a proxy statement with the SEC in connection with seeking stockholder approval of the Dissolution Proposal.

Key Dates

Recommendation

The company is undergoing a formal dissolution process, has been delisted from Nasdaq, and is now trading on the OTC Pink Marketplace. These are definitive indicators of business failure and impending liquidation, which typically results in a significant loss of value for common shareholders. The issuance of special preferred stock is a procedural step to facilitate the dissolution, not a sign of recovery. Investors should exit their positions to minimize further losses.

Keywords

Dissolution, Corporate Governance, Preferred Stock, Delisting, SEC Filing, OTC Pink Marketplace, Shareholder Vote, Corporate Wind-down, Biotechnology